Dermoscopic findings of perifollicular pigmentation associated with vandetanib
Keywords:
cutaneous adverse events, tyrosine kinase inhibitor, pigmentation, dermoscopyPublished
2018-10-31
Issue
Section
Letter
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
1.
Cury-Martins J, Sanches JA. Dermoscopic findings of perifollicular pigmentation associated with vandetanib. Dermatol Pract Concept. 2018;8(4):340-341. doi:10.5826/dpc.0804a20

